Supplementary Material for: Complete Response on Larotrectinib in NTRK2-Fusion positive NSCLC

In patients with non-small cell lung cancer (NSCLC) harboring a fusion of the neurotrophic receptor kinase (NTRK) gene 1 or 3 treatment with tropomyosine kinase (TRK) inhibitors have shown promising results, however so far no data on efficacy of these agents in patients with NSCLC and NTRK2 fusion is available. We present a case of a female patient with NTRK2 positive NSCLC with a complete ongoing response on therapy with larotrectinib, suggesting efficacy of first-generation TRK inhibitors also in NTRK2 positive NSCLC.